microdosing glp-1 tirzepatide Program Microdosing GLP-1 Medications | Achieve

Diabetes 63(12):41864196 Baggio LL, Drucker DJ (2014) Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

By 18 months after discontinuation, most patients have returned to their baseline weight, erasing the majority of their progress

Hypersensitivity reactions have been linked with all DPP4i [166]

This would remove the need for a needle in the GLP-1 weight loss process

A phase 1b clinical trial in Chinese individuals using a MAD study design shows a mean weight loss at 12 weeks of 11.7% at 9 mg, and 9.5% over 16 weeks at 10 mg, versus 1.8% and 3.3% in those who received placebo, respectively (86)

In the sections below, first we provide an overview of the salient findings with regard to the use of GLP1-RAs in experimental models of AD and PD